BeneFIX® (nonacog alfa – recombinant coagulation FIX) is indicated for the treatment and prophylaxis of bleeding in patients with hemophilia B (congenital FIX deficiency).1
BeneFIX® is a recombinant coagulation FIX. Find out how BeneFIX® works
BeneFIX® provides dosing options based on individual needs
Proven efficacy and protection across dosing regimen
Pfizer Products India Pvt. Ltd.,
The Capital-B wing, 1802,18th Floor, Plot
No. C-70, G Block, Bandra Kurla Complex, Bandra (East), Mumbai, India.
Trademark Owner: Wyeth LLC, USA.
Licensed User: Pfizer Products India Pvt. Ltd. India
To view the summary of prescribing information for BeneFIX®, please click here.
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory. Full prescribing information available on request.
FIX, factor IX.
Local product document, Nonacog alfa (recombinant coagulation factor IX), BeneFIX® : LPDBEN062022.
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered medical practitioner*, please visit "https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf", Page No. 39, Rule 2 part (ee), last accessed on 26th April 2021.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.